0001140361-24-013726.txt : 20240318 0001140361-24-013726.hdr.sgml : 20240318 20240318085642 ACCESSION NUMBER: 0001140361-24-013726 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240318 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 24757039 BUSINESS ADDRESS: STREET 1: ROUTE 206 AND PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08543 BUSINESS PHONE: 6092524621 MAIL ADDRESS: STREET 1: ROUTE 206 AND PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08543 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 ef20024275_8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2024

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)


Delaware
001-01136
22-0790350
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)

Route 206 & Province Line Road
Princeton, New Jersey, 08543
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (609) 252-4621


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.10 Par Value
  
BMY
  
New York Stock Exchange
1.000% Notes due 2025
  
BMY25
  
New York Stock Exchange
1.750% Notes due 2035
  
BMY35
  
New York Stock Exchange
Celgene Contingent Value Rights
  
CELG RT
  
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.
Other Events.
 
On March 18, 2024, Bristol-Myers Squibb Company (“BMS”) issued a press release announcing the completion of its previously announced acquisition (the “Acquisition”) of Karuna Therapeutics, Inc. (“Karuna”). In the Acquisition, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the Acquisition (other than certain excluded shares as described in the agreement and plan of merger entered into among BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS) was automatically converted into the right to receive $330.00 in cash, without interest, and subject to any required withholding taxes. A copy of the press release announcing the closing of the Acquisition is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
The following exhibits are included as part of this Current Report on Form 8-K:
 
Exhibit
No.
  
Description
99.1
  
Press Release of Bristol-Myers Squibb Company, dated March 18, 2024.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit
No.
  
Description
 
Press Release of Bristol-Myers Squibb Company, dated March 18, 2024.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
   
Dated: March 18, 2024
By:
/s/ Kimberly M. Jablonski
 
Name:
Kimberly M. Jablonski
 
Title:
Corporate Secretary


EX-99.1 2 ef20024275_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

 
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,
Strengthening Neuroscience Portfolio

KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications

PRINCETON, N.J. – March 18, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).

“We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Importantly, this transaction aligns with our commitment to strengthening BMS’s growth profile in the latter half of the decade and beyond. We look forward to working with Karuna’s talented team to bring KarXT to patients with schizophrenia later this year.”

Through this transaction, BMS has added KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of action and a differentiated efficacy and safety profile, and Karuna’s early-stage and pre-clinical pipeline. KarXT has a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024 for the treatment of schizophrenia in adults. KarXT is also in registrational trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease, with potential to expand to additional indications, including Bipolar I disorder and Alzheimer’s disease agitation.

As previously disclosed, the transaction is expected to be dilutive to Bristol Myers Squibb’s non-GAAP diluted earnings per share by approximately $0.30 in 2024 from the financing cost of the transaction, which is primarily from a recently completed new debt issuance. Bristol Myers Squibb expects to offset the operational expenses of the transaction through continued disciplined resource allocation, cost efficiencies and portfolio prioritization. Bristol Myers Squibb’s cash flows and strong financial profile enable continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases.

The transaction will be accounted for as an asset acquisition resulting in an approximately $12 billion one-time, non-deductible Acquired In-Process Research and Development (Acquired IPR&D) charge impacting both 2024 first quarter and full-year GAAP and non-GAAP EPS by approximately $5.93.

Consistent with past practice, Bristol Myers Squibb generally provides updates to its financial outlook once each quarter. When considering Bristol Myers Squibb’s financial outlook issued on February 2, 2024, investors and analysts should take into account the impacts outlined above. Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024.

Advisors

Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel. Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Karuna, and Simpson Thacher & Bartlett LLP is serving as legal counsel.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” regarding, among other things, the acquisition of Karuna by Bristol Myers Squibb and Bristol Myers Squibb’s anticipated Acquired IPR&D charges for the quarter ending March 31, 2024, and the related impact to its GAAP and non-GAAP earnings per share. These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized, including with respect to the potential commercialization of KarXT, (ii) risks associated with legal proceedings instituted related to the merger agreement (iii) unanticipated difficulties or expenditures relating to the transaction, the response of business partners and competitors to the consummation of the transaction and/or potential difficulties in employee retention as a result of the consummation of the transaction and (iv) completion of Bristol Myers Squibb’s quarter-end closing process, including review by management and the audit committee of the Bristol Myers Squibb’s board of directors, which could result in changes to the preliminary estimates described herein. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2023 and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other documents that may be filed by Bristol Myers Squibb from time to time with the U.S. Securities and Exchange Commission. Bristol Myers Squibb does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made.

Use of Non-GAAP Financial Information and Financial Guidance

In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company’s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods.

Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibb’s business nor reflect Bristol Myers Squibb’s underlying business performance. Similar charges or gains were recognized in prior periods and will likely recur in future periods.

Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

A reconciliation of forward-looking non-GAAP measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not without unreasonable effort, able to reliably predict the impact of accelerated depreciation, and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the non-GAAP financial guidance in this press release excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication.

Media Inquiries:
Media: media@bms.com

Investors:
Investor Relations: investor.relations@bms.com


 EX-101.SCH 3 bmy-20240318.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20240318_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20240318_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock [Member] Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name 1.750% Notes due 2035 [Member] Celgene Contingent Value Rights [Member] 1.000% Notes due 2025 [Member] EX-101.PRE 6 bmy-20240318_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00001.jpg begin 644 image00001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Mar. 18, 2024
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 18, 2024
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Central Index Key 0000014272
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One Route 206 & Province Line Road
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08543
City Area Code 609
Local Phone Number 252-4621
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 5 22 1 false 4 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bmy-20240318.xsd bmy-20240318_def.xml bmy-20240318_lab.xml bmy-20240318_pre.xml ef20024275_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20024275_8k.htm": { "nsprefix": "bmy", "nsuri": "http://bms.com/20240318", "dts": { "schema": { "local": [ "bmy-20240318.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "bmy-20240318_def.xml" ] }, "labelLink": { "local": [ "bmy-20240318_lab.xml" ] }, "presentationLink": { "local": [ "bmy-20240318_pre.xml" ] }, "inline": { "local": [ "ef20024275_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 3, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 5, "entityCount": 1, "segmentCount": 4, "elementCount": 37, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 31 }, "report": { "R1": { "role": "http://bms.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240318to20240318", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20024275_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240318to20240318", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20024275_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "bmy_CelgeneContingentValueRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20240318", "localname": "CelgeneContingentValueRightsMember", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsLineItems", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsTable", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "bmy_One000NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20240318", "localname": "One000NotesDue2025Member", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "auth_ref": [] }, "bmy_One750NotesDue2035Member": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20240318", "localname": "One750NotesDue2035Member", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001140361-24-013726-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-013726-xbrl.zip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ef20024275_8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2024-03-18 2024-03-18 0000014272 us-gaap:CommonStockMember 2024-03-18 2024-03-18 0000014272 bmy:CelgeneContingentValueRightsMember 2024-03-18 2024-03-18 0000014272 bmy:One750NotesDue2035Member 2024-03-18 2024-03-18 0000014272 bmy:One000NotesDue2025Member 2024-03-18 2024-03-18 false 0000014272 8-K 2024-03-18 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 Route 206 & Province Line Road Princeton NJ 08543 609 252-4621 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY25 NYSE 1.750% Notes due 2035 BMY35 NYSE Celgene Contingent Value Rights CELG RT NYSE false